ACE2 and COVID-19: The mostly studied drug targets against COVID-19 include structural proteins of SARS-CoV-2 (spike glycoprotein, envelope protein, neucleocapsid protein), non-structural proteins of SARS-CoV-2 (Mpro, papain-like protease, RNA-dependent RNA polymerase, helicase), host cell target protein, and different cytokine release from host cellular environment (angiotensin-converting enzyme 2, transmembrane serine protease 2), and these are employed to both in silico and wet lab experiment for screening out effective inhibitors (Crosby et al., 2020; Li H. et al., 2020).